Navigation Links
Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Date:5/17/2012

diseases. Dr. Samantha Mary Jaglowski et al. The Ohio State University, Columbus, Ohio. 

Poster Discussion Session at ASCO, Chicago, IL (June 1-5, 2012)
Date/Time: Friday, June 1, 2012; 4:30 PM — 5:30 PM (CT)
Location: S405
Abstract # 6515: Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study.  Dr. Susan M. O'Brien et al. MD Anderson Cancer Center, Houston, Texas.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Pharmacyclics to Host a Conference Call on March 15, 2012 to Discuss Second Quarter Fiscal 2012 Financial and Operational Results
2. Pharmacyclics Inc. Receives Issue Notice of Significant Brutons Tyrosine Kinase (BTK) Patent
3. Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc.
4. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
5. Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
6. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
7. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
8. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
9. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
10. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
11. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... EMERYVILLE, Calif. , June 19, 2013 /PRNewswire/ ... performance management solutions, introduced the next-generation of its ... solution, which allows health plans to provide their ... their populations, health factors, medical and prescription drug ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
(Date:6/19/2013)... June 19, 2013  It may seem like an odd ... breast cancer. But these were two of the most talked ... Annual Meeting & Expo that just convened in ... this focus by some of the top internal medicine experts ... with new research that can not only save lives, but ...
(Date:6/18/2013)... NEW YORK , June 18, 2013  Intercept ... stage biopharmaceutical company focused on the development and commercialization ... diseases, today announced the pricing of an underwritten public ... a public offering price of $33.01 per share.  In ... to purchase up to an additional 259,500 shares of ...
Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... (Nasdaq: DVAX ) today reported that it had ... subjects as,part of an environmental exposure chamber study that ... are being screened based on a history of,ragweed allergy ... in,the chamber is being used to select those individuals ...
... Demonstrate Continued Safety, Consistently Positive Clinical ... ... presented today from,Abbott,s SPIRIT III U.S. pivotal clinical trial demonstrated ... Coronary Stent System at one year, including continued,clinical superiority in ...
Cached Medicine Technology:Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 2Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 2Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 4Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 5
(Date:6/19/2013)... June 19, 2013 The deadline ... is this Friday, June 21 at midnight ET. ... programs and innovative people who’ve raised the bar ... visit http://www.minonline.com/ima . , Any consumer and ... title is eligible to enter. Additionally, advertising agencies ...
(Date:6/19/2013)... Utah (PRWEB) June 19, 2013 Today, ... Wisconsin Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution ... to Zane Benefits’ website, as part of the Affordable ... small businesses will become available through new state health ...
(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...
(Date:6/19/2013)... results of three important studies have been published in ... of the Congress of Neurological Surgeons . ... Wilkins , a part of Wolters Kluwer Health ... using artificial neural networks (ANNs) may improve the ability ... Another study in the June Neurosurgery supports ...
(Date:6/19/2013)... 19, 2013) In early April, senior leaders from ... Hartford, Connecticut, to discuss one question: how can first ... , The preliminary results of this discussion are ... Events: The Hartford Consensus ," a concept paper published ... Journal of Trauma and Acute Care Surgery , ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... 2009 Laboratory market projections.NEWARK, N.J., April 14 ... G-2 Reports indicates that the clinical diagnostic lab ... by 2017. An increase in genetic testing, ... expanded access to healthcare are among the key ...
... Maine, April 14 IDEXX Laboratories, Inc. (Nasdaq: ... 2009 first quarter financial results for Friday, April 24, at ... conference call beginning at 9:00 a.m. (eastern) on that day. ... through a link on the IDEXX Web site, ...
... & Spa,Group, Inc. (OTC Bulletin Board: SOKF), a leading operator ... CEO Liu, Tong, CFO Yu, Xia,and corporate secretary Mu, Yan ... earnings results at 9 am EDT on Thursday,April 16, 2009. ... * US/Canada Toll Free Dial-in #: (866) 811 - 8933, ...
... related blindness by almost 35%, study suggests, , , TUESDAY, ... age-related macular degeneration is on the increase, newer treatments ... disease by about 35 percent, new estimates suggest. , ... Disease Control and Prevention, researchers report that as many ...
... Six New Board of Directors Members Also Appointed and ... Bruce R. Korf, MD, PhD, FACMG, of Birmingham, AL ... Medical Genetics (ACMG), the national professional organization for medical ... President Joe Leigh Simpson, MD, FACMG, of Miami, FL ...
... April 14 Continuing a nine-year tradition of putting ... Lines (NYSE: DAL ) employees today presented ... gift of more than 1,250 handmade quilts. Each quilt, ... airline employees and other volunteers on their own time.(Logo: ...
Cached Medicine News:Health News:Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 2Health News:Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 3Health News:SOKO Fitness & Spa Group, Inc. to hold 2009 Q3 Earnings Call on Apr. 16 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 3Health News:Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics 2Health News:Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics 3Health News:Delta Employees Blanket Salt Lake City Medical Center With Warm Gifts 2
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
... Synchron LXi 725 clinical system combines ... accurate immunoassay testing capabilities, innovative data ... a single platform. After tests are ... for optimal quality assurance. If reflex ...
... Access immunoassay system is ... benchtop analyzer that performs ... with panels that include ... infectious disease, blood virus, ...
...
Medicine Products: